NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of “Moderate Buy” by Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $19.89.

Several equities analysts have commented on NEO shares. Stephens reaffirmed an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Benchmark reaffirmed a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th.

NeoGenomics Stock Up 1.2 %

NASDAQ NEO opened at $16.40 on Monday. NeoGenomics has a 52 week low of $11.03 and a 52 week high of $21.22. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -24.85 and a beta of 1.19. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. The company has a fifty day moving average of $15.82 and a two-hundred day moving average of $14.92.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The company had revenue of $164.50 million for the quarter, compared to analyst estimates of $161.82 million. During the same period in the prior year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, analysts predict that NeoGenomics will post -0.22 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its position in NeoGenomics by 107.2% during the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 1,206 shares during the last quarter. Burkett Financial Services LLC acquired a new stake in shares of NeoGenomics in the 4th quarter worth $46,000. Canada Pension Plan Investment Board purchased a new position in NeoGenomics during the 2nd quarter worth $57,000. Quadrant Capital Group LLC increased its position in NeoGenomics by 22.0% during the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock valued at $79,000 after buying an additional 883 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in NeoGenomics by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,791 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.